Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.
According to a recent study, tirzepatide and semaglutide offer long-term health benefits but are not cost-effective.
Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop ...
More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®As previously a ...
University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity ...
Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
When best friends AnnaLee Canario and Dacia Benjamin started taking weight loss drugs together they thought it would be an ...
Ivim takes a comprehensive approach to obesity care and its customized patient-centric plans are carefully overseen by ...
Researchers analysed data from 150 adults with T1D, divided into semaglutide, tirzepatide, and control groups.
A drug shortage is when a drug manufacturer isn't able to supply enough of a drug to meet all of its Canadian orders on time. The words drug, medication and medicine are often used interchangeably.
Judge Mark Pittman of the Northern District of Texas declined to issue an injunction to stop the Food and Drug Administration (FDA) from declaring there was no longer a shortage of the medicines’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results